Preparatory Documents Available for June 20, 2024, General Meeting

Daix, France, May 30, 2024 – Inventiva, a biopharmaceutical company specializing in developing oral small molecule therapies, has released the preparatory documents for its upcoming Combined General Meeting, scheduled for June 20, 2024. This meeting will take place at Hôtel Castel Burgond in Daix, France.

Invitation to Shareholders

Shareholders are encouraged to attend the meeting, which starts at 9 a.m. The preliminary notice of the meeting, which includes the agenda and draft resolutions, was published in the Bulletin des Annonces Légales Obligatoires (BALO) on May 13, 2024, and translated for the Securities and Exchange Commission on the same day. Detailed information regarding participation and voting can be accessed through the "Investors" and "Shareholder Meetings" sections of Inventiva’s official website.

Document Accessibility

In compliance with French commercial law, required documents will be available at Inventiva's headquarters in Daix from the fifteenth day before the meeting. Further, documents listed under Article R.22-10-23 of the French Commercial Code will be accessible on the company’s website from tomorrow. Shareholders with registered shares can request the documents up to five days before the meeting. Bearer shareholders need to provide a shareholding certificate from their financial intermediary to exercise this right. All shareholders may also view the documents at the company’s office by emailing their requests.

About Inventiva

Inventiva is dedicated to the research and development of small molecule therapies targeting significant unmet medical needs, including metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH). The company has profound expertise in nuclear receptors, transcription factors, and epigenetic modulation. The team comprises around 90 scientists skilled in various fields such as biology, chemistry, pharmacokinetics, and clinical development.

Current Projects and Pipeline

Inventiva's leading candidate, lanifibranor, is in a pivotal Phase III clinical trial (NATiV3) aimed at treating adults with MASH/NASH, a chronic liver disease with no current approved therapies. Additionally, the company has a preclinical pipeline and is exploring other development opportunities. Another product, odiparcil, intended for adult MPS VI patients, has had its clinical efforts suspended as Inventiva focuses on lanifibranor. The company is also advancing its research on the Hippo signaling pathway.

Corporate Structure and Financials

Inventiva is a publicly traded company on Euronext Paris and the Nasdaq Global Market, trading under the ticker IVA. It owns a comprehensive library of approximately 240,000 pharmacologically relevant molecules, with 60% being proprietary. The company operates a fully owned research and development facility.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!